By IDSE News Staff
New START data confirm that starting antiretroviral treatment (ART) early in the course of HIV infection when the immune system is stronger results in better long-term health outcomes compared with delaying ART, according to findings presented at IDWeek 2022, in Washington, D.C.
In 2015, the START (Strategic Timing of Antiretroviral Treatment) study demonstrated a 57% reduced risk for AIDS and serious non-AIDS health outcomes among participants who began ART when their CD4+